Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 MAR 9 ... CTIC) announced that it exercised its option to sell its 50% ownership interest in the Zevalin joint venture to Spectrum Pharmaceuticals, Inc. (Spectrum) for $18 million. CTI and ...
2009 JAN 19 ... venture transaction with Spectrum Pharmaceuticals, Inc. to commercialize and develop Zevalin(R) in the United States. In December, the Company received the initial $7.5 million ...
2009 JAN 26 ... to obtain two new drug approvals in 2009 in addition to potential label expansion for Zevalin(R). In November CTI established a 50/50 joint venture with Spectrum Pharmaceuticals, ...
2009 MAR 30 ... review for the application. Potential approval by end of
2009. -- Zevalin sales prior to the establishment of the joint venture with
Spectrum ...
2009 APR 20 ... Pharmaceuticals, Inc. (Spectrum) in connection with the sale of its 50% interest in the Zevalin joint venture to Spectrum for approximately $16.5 million that closed in March 2009. CTI ...
2009 FEB 16 ... spectrum by lead was calculated. Whole-body and finger doses to persons preparing (90)Y-Zevalin were measured. Good laboratory practice is important to keep radiation doses low. To ...
2009 JUN 1 ... for multiple drug development programs in Phase 1 to Phase 4 clinical trials, including Zevalin(R) and Rituxan(R).
Before his career in industry, Dr. Multani held ...
2009 JAN 12 ... radiation dose delivered from patients injected with yttrium-90 (Y)-labelled tiuxetan (Zevalin) to parents and the general population, comparing different techniques. The radiation ...
2009 MAR 2 ... IDEC research team through the discovery and pre-clinical development of Rituximab and Zevalin, two antibodies now approved for therapy of non-Hodgkin's lymphoma.
...
2009 NOV 2 ... lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin,' is newly published data in European Journal of Nuclear Medicine and Molecular ...
2009 JAN 12 ... dose delivered from patients injected with yttrium-90 (Y-90)-labelled tiuxetan (Zevalin) to parents and the general population, comparing different techniques. The radiation ...
2009 FEB 23 ... Lymphoma, Nuclear Medicine, Oncology, Pharmaceuticals, Therapy, Tositumomab, Treatment, Zevalin.
This article was prepared by Biotech Business Week editors from staff ...
2009 MAR 23 ... to recent research from the United States, "(90)Yttrium-ibritumomab-tiuxetan (Zevalin) is an effective treatment for relapsed or refractory low-grade, follicular, or ...
2009 MAR 30 ... Spectrum Pharmaceuticals acquired 100% control of RIT Oncology, LLC™, to commercialize ZEVALIN® ([90Y]-ibritumomab tiuxetan) in the United States. In connection with the closing, ...
2009 APR 13 ... look forward to numerous important milestones in 2009.” Major Value Drivers for 2009: ZEVALIN® July approval decision by FDA regarding use in 1st line consolidation treatment for ...
2009 AUG 31 ... the quarter, we made significant progress toward stabilizing, and ultimately growing, ZEVALIN® sales, even before its approval in the first line setting," said Rajesh C. ...
2009 FEB 2 ... 15, 2009 in the Annals of Oncology demonstrating that rituximab followed by single agent Zevalin (ibritumomab tiuxetan) in a front-line setting for patients with MALT lymphoma and low- ...
2008 DEC 29 ... form a 50/50 owned joint venture, RIT Oncology LLC (LLC), to commercialize and develop Zevalin(R) ([90Y]-ibritumomab tiuxetan) in the United States. In connection with the closing, ...
